TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28476710
Drug: Minimally invasive
Normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally invasive interventional therapy
Study: 28476710
Drug: Drug conservative
Normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug conservative therapy
Study: 20417052
Drug: Dual-DES (Dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-DES (Dual Drug-Eluting Stent)
Study: 15633203
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg/day) for 8 weeks
Study: 15633203
Drug: Montelukast (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (5 mg/day) for 8 weeks (crossover group)
Study: 1993791
Drug: Inferior left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior left ventricular patch as an anode
Study: 1993791
Drug: Inferior left
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inferior left ventricular patch as a cathode
Study: 6389814
Drug: Written instructions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written instructions for mixing the solution along with a pre‐marked container (group I)
Study: 30308388
Drug: Palbociclib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (125 mg/d; 3/1 schedule) plus fulvestrant (500 mg)
Study: 26853648
Drug: CMVPepVax vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMVPepVax vaccine
Study: 21640257
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye 0.5 mg every 4 weeks
Study: 21640257
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye 2 mg every 4 weeks
Study: 21640257
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye 0.5 mg every 12 weeks
Study: 21640257
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye 2 mg every 12 weeks
Study: 21640257
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye 4 mg every 12 weeks
Study: 21640257
Drug: VEGF Trap‐Eye
Approvals — FDA: no, EMA: no, PMDA: no
Description: VEGF Trap‐Eye (2 mg q4wk and 2 mg q12wk)
Study: 19459420
Drug: One combined
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One combined inhaled drug containing glucocorticosteroids (GCS) and long‐acting beta2‐agonists (LABA)
Study: 8101126
Drug: Alprazolam and
Normalized name: Alprazolam and propranolol only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam and exposure (combined treatment)
Study: 3434999
Drug: Home preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home preparation with 3 liters balanced electrolyte solution (BES)
Study: 3434999
Drug: Hospital preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital preparation with 3 liters balanced electrolyte solution (BES)
Study: 29527927
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BR) administration
Study: 27176869
Drug: LGP‐HAL (Restylane
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGP‐HAL (Restylane Lyft; Galderma Laboratories, L.P.)
Study: 20728636
Drug: THC (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (13 mg)
Study: 20728636
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of alcohol and THC
Study: 8151912
Drug: S6472 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 capsules (375 mg, twice a day for 7 days)
Study: 8151912
Drug: S6472 granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 granules (375 mg, twice a day for 7 days)
Study: 8151912
Drug: S6472 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 capsules
Study: 8151912
Drug: S6472 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: S6472 capsules and granules
Study: 3280080
Drug: Flutamide 750
Normalized name: Flutamide
DrugBank: Flutamide (DB00499)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flutamide 750 mg daily
Study: 3280080
Drug: Stilboestrol 3
Normalized name: Stilboestrol
DrugBank: Diethylstilbestrol (DB00255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stilboestrol 3 mg daily
Study: 26538427
Drug: IT +
Normalized name: RE PreVit + DHA Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: IT + HBO treatment
Study: 26538427
Drug: IV +
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV + HBO therapy
Study: 25376735
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol) at a high dose of 100,000 UI every 2 weeks for 2 months then monthly for 22 months
Study: 25376735
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol) at a low dose of 12,000 UI every 2 weeks for 2 months then monthly for 22 months
Study: 25376735
Drug: High-dose cholecalciferol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose cholecalciferol (100,000 IU)
Study: 25376735
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol (12,000 IU)
Study: 10407712
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.25 mg BID
Study: 10407712
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.5 mg BID
Study: 10407712
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 1 mg QD
Study: 10407712
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension 0.25 mg QD
Study: 7539817
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human growth hormone (rhGH; 0.025 mg/kg.day)
Study: 7539817
Drug: low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose recombinant human insulin-like growth factor-I (rhIGF-I; 0.015 mg/kg, twice daily)
Study: 7539817
Drug: high dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose recombinant human insulin-like growth factor-I (rhIGF-I; 0.060 mg/kg, twice daily)
Study: 2161626
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg 3 times a day)
Study: 81412
Drug: Hypertransfusion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertransfusion to a haemoglobin of 16‐‐18 g/dl (group B)
Study: 81412
Drug: Transfusion to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transfusion to a haemoglobin of 10‐‐12 g/dl (group A)
Study: 23982564
Drug: Intra-articular corticosteroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular corticosteroid injection (IACI) of 80 mg of methylprednisolone acetate (MPA)
Study: 23982564
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection (IAI) of 6 ml (60 mg) of sodium hyaluronate (control group)
Study: 17219379
Drug: Intramuscular polyestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular polyestradiol phosphate (PEP) 240 mg/month
Study: 17219379
Drug: Intramuscular polyestradiol
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular polyestradiol phosphate (PEP)
Study: 15857105
Drug: 1% pimecrolimus
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% pimecrolimus cream applied twice daily for 4 weeks
Study: 11213071
Drug: Interferon-alpha2a, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha2a, 3 mU daily for 12 months
Study: 7939127
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with stimulant medications
Study: 7939127
Drug: Daily distribution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily distribution of cataplexy attacks
Study: 2463720
Drug: Diprafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diprafenone 450 mg/day
Study: 3057844
Drug: Propafenone 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone 450 mg/day
Study: 29602883
Drug: Danegaptide high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danegaptide high dose
Study: 29602883
Drug: Danegaptide low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danegaptide low dose
Study: 26817346
Drug: Tocolytic drugs
Normalized name: Telomerase Specific Replication-competent Oncolytic Adenovirus
DrugBank: Suratadenoturev (DB18672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocolytic drugs
Study: 19005298
Drug: Optimal Medical
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal Medical Treatment (Control)
Study: 15276957
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for neuropsychiatric symptoms of TBI
Study: 8694318
Drug: Somatosensory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatosensory stimulation with 60 electric pulses (20 mA, 0.2 ms) to the tips of the fingers for 10 min, followed by continued stimulation for 20 min after anesthetic injection.
Study: 1311661
Drug: Intralipid infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid infusion (20% w/v, 1 ml/min for 120 min) during hyperinsulinaemic euglycaemic clamp (100 m-units h-1 kg-1)
Study: 1311661
Drug: Control (0.154
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0.154 mol/l NaCl infusion)
Study: 2984913
Drug: Enalapril (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (5 to 20 mg twice daily)
Study: 2984913
Drug: Captopril (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (25 to 100 mg thrice daily)
Study: 2984913
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor placebos
Study: 2984913
Drug: Alpha-methyldopa (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-methyldopa (250 to 500 mg twice daily)
Study: 24119443
Drug: 5-FU/oxaliplatin chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU/oxaliplatin chemotherapy
Study: 21828031
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg every 6 h until neutropenia)
Study: 19484628
Drug: Rivastigmine (Exelon)
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine (Exelon) at a maximum dose of 12 mg daily for 8 weeks
Study: 17252021
Drug: Control (timed‐sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (timed‐sequential induction regimen alone)
Study: 17252021
Drug: Control (timed‐sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (timed‐sequential consolidation without GM‐CSF)
Study: 10086836
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg dose of dolasetron mesylate solution
Study: 10086836
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg dose of dolasetron mesylate solution
Study: 10086836
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg dose of dolasetron mesylate solution
Study: 7733082
Drug: Naproxen 500
Normalized name: naproxen 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 500 mg p.o. b.i.d. for 1 week
Study: 2056362
Drug: Lorazepam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.05 mg/kg)
Study: 6122327
Drug: Oxycodone (0.14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone (0.14 mg/kg)
Study: 6368765
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics (Vancomycin and Gentamicin administered systemically, Streptomycin in irrigating solution)
Study: 30544795
Drug: Spirulina maxima
Normalized name: SPIRULINA MAXIMA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spirulina maxima (4.5 g for 12 weeks)
Study: 20381660
Drug: High doses
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High doses of NSAIDs
Study: 12167942
Drug: Active sodium
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active sodium bicarbonate oral composition
Study: 9012623
Drug: Albuterol 100
Normalized name: ALBUTEROL 100/IPRATRO 20MCG 120D PO INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 100 micrograms via Turbuhaler (2 x 50 micrograms)
Study: 9012623
Drug: Albuterol 200
Normalized name: ALBUTEROL 200MCG CAP,INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 200 micrograms via pMDI (2 x 100 micrograms)
Study: 9012623
Drug: Albuterol 100
Normalized name: ALBUTEROL 100/IPRATRO 20MCG 120D PO INHL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albuterol 100 micrograms via Turbuhaler
Study: 7881024
Drug: Intravenous human
Normalized name: botulism immune globulin IV human Injection [BabyBIG]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous human epidermal growth factor (hEGF) 6 micrograms twice a week
Study: 3203698
Drug: Increased daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased daily fluid intake (1.51 liters per day)
Study: 3203698
Drug: Standard daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard daily fluid intake (3.01 liters per day)
Study: 31844950
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid with hydrodilatation (distension group)
Study: 31844950
Drug: Only intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only intra-articular steroid (non-distension group)
Study: 31844950
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid with hydrodilatation (distension group) among diabetics
Study: 31844950
Drug: Only intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only intra-articular steroid (non-distension group) among diabetics
Study: 31844950
Drug: Intra-articular steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular steroid with hydrodilatation (distension group) among diabetic and non-diabetic patients
Study: 31844950
Drug: Only intra-articular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only intra-articular steroid (non-distension group) among diabetic and non-diabetic patients
Study: 26391390
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) with orally administered estrogen and medroxyprogesterone acetate
Study: 20920040
Drug: Phentermine DCR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentermine DCR 30 mg
Study: 22184409
Drug: 4 biweekly
Normalized name: Biweekly Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 biweekly doses of gemcitabine, vinorelbine, and liposomal doxorubicin (if positive FDG-PET scan)
Study: 19815600
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and alternative medicine (CAM) therapies
Study: 17481702
Drug: Optical Detection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optical Detection System (ODS) used as an adjunct to colposcopy
Study: 12192196
Drug: Epinephrine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epinephrine (5 to 10 mL of 1:10,000 epinephrine)
Study: 12192196
Drug: Fibrin sealant
Normalized name: FIBRIN SEALANT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrin sealant (4 mL)
Study: 27875526
Drug: Caphosol (topically
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caphosol (topically administered, rinsed orally four times daily from initiation of conditioning through day +20)
Study: 27875526
Drug: Placebo saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo saline rinses (four times daily from initiation of conditioning through day +20)
Study: 26553688
Drug: PsA‐TT (MenAfriVac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PsA‐TT (MenAfriVac) vaccine
Study: 26553688
Drug: Quadrivalent polysaccharide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent polysaccharide vaccine (PsACWY)
Study: 21621834
Drug: NV1FGF at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NV1FGF at 0.2 mg/mL
Study: 19615809
Drug: Mineral Oil
Normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineral Oil (CryoBioSystem, L'Aigle, France)
Study: 17540966
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy with investigational motor cortex stimulation
Study: 17540966
Drug: Rehabilitation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rehabilitation therapy without investigational motor cortex stimulation
Study: 15130570
Drug: Individualised acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised acupuncture (up to 10 treatments)
Study: 9697378
Drug: 2% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide three times daily
Study: 8764800
Drug: 2% dorzolamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% dorzolamide twice daily
Study: 3902498
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oxitropium bromide (200 micrograms) and salbutamol (200 micrograms)
Study: 22866909
Drug: Vaginal natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal natural progesterone, 200 mg daily from 22 to 34 weeks gestation
Study: 19386947
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg) with nitazoxanide (500 mg, twice daily for 6 days)
Study: 19386947
Drug: Warfarin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (25 mg) alone and Warfarin (25 mg) with nitazoxanide (500 mg, twice daily for 6 days)
Study: 17697099
Drug: Computerized tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized tests (Cognitive Drug Research)
Study: 15681761
Drug: Keyhole limpet
Normalized name: Keyhole limpet hemocyanin
DrugBank: Keyhole limpet hemocyanin (DB05299)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Keyhole limpet hemocyanin (KLH) feeding on days 1 to 5 and 11 to 15, followed by subcutaneous immunization with KLH on day 26 and a booster on day 35.
Study: 11587159
Drug: Trandolapril (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (2 mg oral for 12 weeks)
Study: 11587159
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg oral for 12 weeks)
Study: 391678
Drug: Essaven capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essaven capsules (3 X 2 capsules per day)
Study: 28290119
Drug: Carbamazepine controlled-release
Normalized name: carbamazepine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine controlled-release monotherapy
Study: 23343829
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (1%)
Study: 23343829
Drug: Topical normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical normal saline (0.9% NaCl)
Study: 16706573
Drug: epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epoetin alfa 40,000 units weekly
Study: 15807203
Drug: Lactobacillus supplement
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus supplement (LB)
Study: 15807203
Drug: Fluid milk
Normalized name: MILK
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid milk (L)
Study: 8971943
Drug: Heparin-coated ECC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated ECC
Study: 8115196
Drug: Active distraction
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active distraction technique (blowing out air during injection)
Study: 3352906
Drug: Controlled‐release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled‐release carbidopa/levodopa preparation
Study: 19665260
Drug: Any of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any of the preoperative skin‐ and nail‐preparation methods studied
Study: 16942564
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy 300 IR (Group 3)
Study: 16942564
Drug: Incremental doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incremental doses up to 500 IR (Groups 1 and 2)
Study: 16942564
Drug: Constant dose
Normalized name: constant albicans extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant dose of 500 IR (Group 4)
Study: 8717103
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 25 mg/week
Study: 24332516
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream once daily for 6 weeks (superficial) or 12 weeks (nodular)
Study: 25526832
Drug: Immediate Treatment
Normalized name: Aquaphor Immediate Relief Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Treatment (IT) group
Study: 22209192
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment (DT) group
Study: 21712288
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine (Oramorph)
Study: 21712288
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone (Oxynorm)
Study: 16567812
Drug: Insulin/dextrose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin/dextrose infusion therapy
Study: 10764173
Drug: Peroperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peroperative morphine titration (3 mg i.v. every 5 or 10 min until respiratory rate decreased)